GenSight raises nearly €3.7 million via share and warrant issue

GenSight Biologics has completed a fundraising round totalling €3,694,665.92, through subscriptions by its three existing shareholders — Heights Capital, Invus and Alumni Capital — using the same share-plus-warrant structure as its July private placement. The company said it will use up to 75 % of the net proceeds to advance its lead gene therapy candidate, […] The post GenSight raises nearly €3.7 million via share and warrant issue appeared first on Longevity.Technology.